Proactive Investors - Run By Investors For Investors

Evgen Pharma ready to prove broccoli drug's worth

Can a humble molecule with a heritage in broccoli really cure any number of ailments?
That’s the premise behind Evgen Pharma (LON:EVG) and chief executive Stephen Franklin says that after eight years of development work, the company has arrived at the business end of proving it.
A phase II trial for the molecule, sulforaphane, as a treatment for a rare form of stroke has just got underway, while the company also has the funds for a breast cancer trial.
Results due in 2018 and Franklin says all investors have to do until then is hold their nerve.

Meet Faron Pharmaceuticals Ltd, Belvoir Lettings, Silence Therapeutics PLC, ANGLE PLC and ReNeuron Group PLC at our event, London , 23 May 2019. Register here »
View full EVG profile View Profile

Evgen Pharma Timeline

December 12 2018
October 21 2015

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use